Two patients with inoperable prostate cancer have made dramatic recoveries after receiving one dose of an experimental drug that is creating excitement among cancer specialists. The results were so startling that researchers decided to release details of the two cases before the drug trial - in which the patients took part - was complete. Doctors said their progress had exceeded all expectations. The men were treated at the Mayo Clinic in Minnesota in the US, one of the top medical centres in the world. Dr Eugene Kwon, the urologist who was in charge of their treatment, compared the results to the first pilot breaking the sound barrier. "This is one of the Holy Grails of prostate cancer research. We have been looking for this for years," he said. Prostate cancer is the most common cancer in men - 34,000 new cases and more than 10,000 deaths are reported each year in Britain, where rates of its occurrence have tripled in the past 30 years, mainly due to improved detection. The US has the highest incidence of the disease.
Two patients with inoperable prostate cancer have made dramatic recoveries after receiving one dose of an experimental drug that is creating excitement among cancer specialists.
The results were so startling that researchers decided to release details of the two cases before the drug trial - in which the patients took part - was complete. Doctors said their progress had exceeded all expectations. The men were treated at the Mayo Clinic in Minnesota in the US, one of the top medical centres in the world.
Dr Eugene Kwon, the urologist who was in charge of their treatment, compared the results to the first pilot breaking the sound barrier.
"This is one of the Holy Grails of prostate cancer research. We have been looking for this for years," he said.
Prostate cancer is the most common cancer in men - 34,000 new cases and more than 10,000 deaths are reported each year in Britain, where rates of its occurrence have tripled in the past 30 years, mainly due to improved detection. The US has the highest incidence of the disease.
All it does is raise false hopes cos even with an accelerated research programme this won't hit the shelves for a decade. keep to the Fen Causeway
